3‐hydroxy 3‐methylglutaryl coenzyme A reductase increase is essential for rat muscle differentiation

3‐Hydroxy 3‐methylglutaryl coenzyme A reductase (HMG‐CoAR) is the key and rate‐limiting enzyme of cholesterol biosynthetic pathway. Although HMG‐CoAR activity has already been related to the differentiation of some cellular lines there are no studies that analyze the role of HMG‐CoAR, and the pathway it is involved with in a fully characterized muscle differentiation model. Thus, the aim of this work is to evaluate such role and delineate the pathway involved in foetal rat myoblasts (L6) induced to differentiate by insulin—a standard and feasible model of the myogenic process. The results obtained by biochemical and morphological approaches demonstrate that (i) HMG‐CoAR increase is crucial for differentiation induction, (ii) p21waf, whose increase is a necessary requisite for differentiation to occur, rises downstream HMG‐CoAR activation, (iii) the main role of p38/MAPK as key regulator also for HMG‐CoAR. Pathologies characterized by muscle degeneration might benefit from therapeutic programmes committed to muscle function restoration, such as modulation and planning myoblast differentiation. Thus, the important role of HMG‐CoAR in muscular differentiation providing new molecular basis for the control of muscle development can help in the design of therapeutic treatment for diseases characterized by the weakening of muscular fibers and aging‐related disorders (sarcopenia). J. Cell. Physiol. 220: 524–530, 2009. © 2009 Wiley‐Liss, Inc.

[1]  Manoel Luis Costa,et al.  Wnt/beta-catenin pathway activation and myogenic differentiation are induced by cholesterol depletion. , 2009, Differentiation; research in biological diversity.

[2]  J. Tong,et al.  AMP-activated protein kinase and adipogenesis in sheep fetal skeletal muscle and 3T3-L1 cells. , 2008, Journal of animal science.

[3]  Manoel Luis Costa,et al.  A soluble and active form of Wnt‐3a protein is involved in myogenic differentiation after cholesterol depletion , 2007, FEBS letters.

[4]  井上 訓之.  Lipid synthetic transcription factor SREBP-1a activates p21[WAF1/CIP1], a universal cyclin-dependent kinase inhibitor , 2007 .

[5]  S. Harridge.  Plasticity of human skeletal muscle: gene expression to in vivo function , 2007, Experimental physiology.

[6]  V. Pallottini,et al.  Caloric restrictions affect some factors involved in age‐related hypercholesterolemia , 2007, Journal of cellular biochemistry.

[7]  Manoel Luis Costa,et al.  Wnt/β-catenin pathway activation and myogenic differentiation are induced by cholesterol depletion , 2007 .

[8]  Yoshiyuki Tanaka,et al.  Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner. , 2007, The Journal of toxicological sciences.

[9]  R. Busse,et al.  Fluid Shear Stress and NO Decrease the Activity of the Hydroxy-Methylglutaryl Coenzyme A Reductase in Endothelial Cells via the AMP-Activated Protein Kinase and FoxO1 , 2007, Circulation research.

[10]  Lisa Christopher-Stine,et al.  Statin myopathy: an update , 2006, Current opinion in rheumatology.

[11]  Z. Yablonka-Reuveni,et al.  The Skeletal Muscle Satellite Cell: The Stem Cell That Came in From the Cold , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  A. Keren,et al.  The p38 MAPK signaling pathway: A major regulator of skeletal muscle development , 2006, Molecular and Cellular Endocrinology.

[13]  G. Falcone,et al.  Fine Regulation of RhoA and Rock Is Required for Skeletal Muscle Differentiation* , 2006, Journal of Biological Chemistry.

[14]  D. Hardie,et al.  AMPK: a key sensor of fuel and energy status in skeletal muscle. , 2006, Physiology.

[15]  Joseph L. Goldstein,et al.  Protein Sensors for Membrane Sterols , 2006, Cell.

[16]  H. Sone,et al.  Lipid Synthetic Transcription Factor SREBP-1a Activates p21WAF1/CIP1, a Universal Cyclin-Dependent Kinase Inhibitor , 2005, Molecular and Cellular Biology.

[17]  M. Kamphuis,et al.  Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  G. Prendergast,et al.  Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. , 2000, Seminars in cancer biology.

[19]  S. Sebti,et al.  RhoA Prenylation Is Required for Promotion of Cell Growth and Transformation and Cytoskeleton Organization but Not for Induction of Serum Response Element Transcription* , 2000, The Journal of Biological Chemistry.

[20]  D. Hardie,et al.  Distinct type‐2A protein phosphatases activate HMGCoA reductase and acetyl‐CoA carboxylase in liver , 1997, FEBS letters.

[21]  J. Wright,et al.  Studies on the effect of mevinolin (lovastatin) and mevastatin (compactin) on the fusion of L6 myoblasts , 1993, Molecular and Cellular Biochemistry.

[22]  D. Hardie,et al.  Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase. , 1992, Biochimica et biophysica acta.

[23]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[24]  A. Pontecorvi,et al.  Selective degradation of mRNA: the role of short‐lived proteins in differential destabilization of insulin‐induced creatine phosphokinase and myosin heavy chain mRNAs during rat skeletal muscle L6 cell differentiation. , 1988, The EMBO journal.

[25]  A. Mauro.  SATELLITE CELL OF SKELETAL MUSCLE FIBERS , 1961, The Journal of biophysical and biochemical cytology.

[26]  C. Marcocci,et al.  Role of the cholesterol biosynthetic pathway in osteoblastic differentiation. , 2007, Journal of endocrinological investigation.

[27]  R. Busse,et al.  Fluid Shear Stress and NO Decrease the Activity of the Hydroxy-Methylglutaryl Coenzyme A Reductase in Endothelial Cells via the AMP-Activated Protein Kinase and FoxO 1 , 2007 .